TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06057077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide weekly injection
Description: semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
Study: NCT04736394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 single-agent oral treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride
Description: Epirubicin hydrochloride
Study: NCT05188196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar ridge preservation
Description: Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar ridge preservation
Description: Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
Study: NCT04882280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light
Description: 10 hours of light exposure during the daytime, starting 2 hours after habitual wake time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light
Description: 10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
Study: NCT05826834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ball-rolling (Myostorm ball)
Description: the intervention group
Study: NCT05042791

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiation combined with pyrotinib and capecitabine
Description: This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: radiation combined with pyrotinib and capecitabine
Description: This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
Study: NCT05886751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Doctor Screening Video
Description: Participants will view an online video with a Black doctor speaking about prostate cancer screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Doctor Screening Video
Description: Participants will view an online video with a White doctor speaking about prostate cancer screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Patient Screening Video
Description: Participants will view an online video with a Black patient speaking about prostate cancer screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Patient Screening Video
Description: Participants will view an online video with a White patient speaking about prostate cancer screening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Doctor Clinical Trials Video
Description: Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Doctor Clinical Trials Video
Description: Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Patient Clinical Trials Video
Description: Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Patient Clinical Trials Video
Description: Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
Study: NCT06641037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3866288
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3866288
Description: Administered orally
Study: NCT05591079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159 (Linafexor)
Description: Oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159 (Linafexor)
Description: Oral QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS0159 (Linafexor)
Description: Oral QD
Study: NCT05718297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
Study: NCT05447923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo education for colorectal cancer screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Undergo FIT testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Undergo patient navigation for positive FIT results

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire about colorectal cancer screening and healthcare
Study: NCT04624230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
Study: NCT06310564

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected \[10\]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data.~In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered.~SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest.
Study: NCT06294951

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
Study: NCT05761067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Alternative treatment
Study: NCT06054308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSLN CART
Description: Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
Study: NCT05609253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole in capsule form
Description: Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole in solution form
Description: Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
Study: NCT06454188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG [Rinvoq]
Description: 15mg tablet once per day.
Study: NCT05896761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study: NCT06454188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15mg tablet once per day.
Study: NCT05871125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reimbursement
Description: Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
Study: NCT06175611

Intervention type: DEVICE
Intervention: COVID-19/Flu A/Flu B/RSV Test Kit
Description: The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

Intervention type: DEVICE
Intervention: COVID-19/Flu A/Flu B/RSV Test Kit
Description: The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.

Intervention type: DEVICE
Intervention: COVID-19/Flu A/Flu B/RSV Test Kit
Description: The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants.
Study: NCT05453968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berotralstat
Description: Administered orally once daily at a weight-based dose in up to 4 cohorts
Study: NCT05454982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
Study: NCT06528418

Intervention type: OTHER
Intervention: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
Description: Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID

Intervention type: OTHER
Intervention: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
Description: Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
Study: NCT06168006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
Study: NCT06562543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Oral capsules
Study: NCT05014880

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ICR (Intensive Cardiac Rehabilitation)
Description: Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)
Description: Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
Study: NCT05239442

Intervention type: OTHER
Group type: OTHER
Intervention: Taste Commission
Description: Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe.

Intervention type: OTHER
Group type: OTHER
Intervention: Taste Commission
Description: Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the taste commissions
Description: At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the taste commissions
Description: At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)

Intervention type: OTHER
Group type: OTHER
Intervention: Entretien SWOT
Description: Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.

Intervention type: OTHER
Group type: OTHER
Intervention: Entretien SWOT
Description: Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
Study: NCT04576429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: venous puncture
Description: Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous puncture
Description: Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tumoral biopsy
Description: Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumoral biopsy
Description: Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
Study: NCT05393674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Oral Capsule [Inrebic]
Description: 400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg every 2 weeks i.v. from cycle 2-n
Study: NCT05103631

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CATCH T cells
Description: Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.
Study: NCT05485155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-proteinase inhibitor
Description: Intravenous infusion at 120 mg/kg body weight dose/week for 8 weeks for a total of 8 infusions.
Study: NCT06276972

Intervention type: OTHER
Intervention: no intervention
Description: there's no intervention. it's a cross sectional study correlation study
Study: NCT06547645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Acute Rehab at Home
Description: Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
Study: NCT04880070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Treatment
Description: Self-controlled, single-arm group using the Shockwave device.
Study: NCT05304520

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.